EuroPCR25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Paris20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

The year in intervention:EuroIntervention and the European Heart Journal

Selected by:

Professor Andrew BoyleJohn Hunter Hospital, Newcastle

Date of preparation May 2014 │BRI001132

Disclaimer

• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.

• These highlights have been suggested by a group of cardiologists who attended EuroPCR 2014, compiled by an external medical writer and sponsored by AstraZeneca. 

• AstraZeneca has obtained permission from EuroPCR, to utilise the selected content for educational purposes.

• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.  Presentations are intended for educational purposes only and do not replace independent professional judgement.

• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.

AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroIntervention 2014; 9: 1271-1284.

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

Between one and three years:

• late luminal loss remained unchanged (6 months: 0.19 mm, 1 year: 0.27 mm, 2 years: 0.27 mm, 3 years: 0.29 mm)

• in-segment angiographic restenosis rate at 3 years was 6%.

EuroPCR 2014Paris

20-23 May 2014

• On IVUS, mean lumen, scaffold, plaque and vessel area showed enlargement up to 2 years.

• Mean lumen and scaffold area remained stable between 2 and 3 years whereas significant reduction in plaque behind the struts occurred with a trend toward adaptive restrictive remodelling of EEM.

• Hyperechogenicity of the vessel wall, a surrogate of the bioresorption process, decreased from 23.1% to 10.4% with a reduction of radiofrequency backscattering for dense calcium and necrotic core.

EuroPCR 2014Paris

20-23 May 2014

• At 3 years, the count of strut cores detected on OCT increased significantly, probably reflecting the dismantling of the scaffold; 98% of struts were covered.

• The 3-year major adverse cardiac event rate was 10.0% without any scaffold thrombosis.

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

“A limitation of the SYNTAX Score is its notable intra-observer and interobserver variability, which can cause inappropriate revascularization strategies.”